For further information please contact:
Porter Novelli for Shire
Jennifer Anello 212.601.8132 email@example.com
203.470.0836 (on site at meeting)
Alana Brier 212.601.8432 firstname.lastname@example.org
October 25, 2007; 11:00 a.m. EDT
Long-Term (Up To 12 Months) Use of the Methylphenidate Transdermal System Frank A. Lopez, M.D., Oscar G. Bukstein, M.D., Robert L. Findling, M.D., John M. Turnbow, M.D., Jonathan Rubin, M.D.
Children's Developmental Center, Winter Park, FL; Western Psychiatric Institute and Clinic, Pittsburgh, PA; University Hospitals Case Medical Center, Cleveland, OH; Westex Clinical Investigations, Lubbock, TX; Shire Development Inc., Wayne, PA.
Important Safety Information
Tell your doctor about any heart conditions, including structural abnormalities, your child or a family member may have. Inform your doctor immediately if the child develops symptoms that suggest heart problems, such as chest pain or fainting.
Daytrana should not be used if the child has: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients of Daytrana; glaucoma; discontinued in the last 14 days or is taking a monoamine oxidase inhibitor (MAOI); tics, or family history or diagnosis of Tourette's syndrome.
Tell your doctor before using Daytrana if the child: is being treated
for or has symptoms of depression (e.g. sadness, worthlessness, or
hopelessness) or bipolar disorder; has family history of tics; has abnormal
thoughts or visions, hears abnormal sounds, or has been diagnosed with
psychosis; has had seizures or abnormal EEGs; has or has had high blood
pressure; exhibits aggressive behavior or hostility. Te
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved